pharmADN is a pioneering national laboratory designed to produce innovative therapies to contribute last-generation solutions for human health care. It is part of a public – private research, development and innovation consortium. Equipped with state-of-the-art technology, the plant produces monoclonal antibodies for treating different types of cancer (breast, lung, colon and rectum), as well as autoimmune diseases, including rheumatoid arthritis.
Stringent biosafety standards are followed in the local production of biopharmaceuticals that have a high impact on health care. Production is used for meeting domestic demand at affordable costs, as well as for exporting to other countries in the region.
The pharmADN plant articulates the national scientific system with the production sector, and is complemented with the Sinergium Biotech plant, which carries out the formulation and packaging of these biotechnology pharmaceuticals.